ExoDx Prostate Test
The ExoDx Prostate Test is an independent risk assessment of clinically significant prostate cancer to assist biopsy decision with in-office or at-home collection available. ExoDx is independent of DRE, PSA, and other standard of care features validated with Level 1 evidence and covered by Medicare and many commercial providers.
Exosome Diagnostics, a subsidiary of mdxhealth, commercializes non-invasive biomarker diagnostic solutions to benefit clinical outcomes, patients and physicians alike.
Empecemos con el kit de recolección de exámenes de próstata ExoDx™ Prostate (EPI)
The ExoDx Prostate test for Risk Assessment of high grade prostate cancer (HGPCa)
ExoDx Prostate Test -A Non-Invasive Liquid Biopsy for Prostate Cancer
The ExoDx Prostate Test: Use in Men With Elevated PSA levels 2-10ng/mL
Getting Started with the ExoDx Prostate Test
Beyond PSA: New Tools for the PSA for Early Detection of Prostate Cancer
Detection of MISEV recommended EV Protein-Markers using Automated Western Blotting
ExoDx Prostate and ZERO - The End of Prostate Cancer - Facebook Live
How the ExoDx Prostate Test Impacts Urology Practice in a Real-World Clinical Setting
ExoDx™ Prostate Test - A Solution to Address Fear of the Prostate Biopsy Decision
Webinar - Beyond PSA: The ExoDx Prostate™ test (EPI) as a Precision Genomic Biomarker
The ExoDx™ Prostate Test: Prostate Cancer and Implications for Value Based Care Part 2
The ExoDx™ Prostate Test: Prostate Cancer and Implications for Value Based Care Part 1
The Power of Exosomes Diagnostic Applications and Beyond
Exosome Enabled Molecular Analysis: Part 2
Exosome Enabled Molecular Analysis: Part 1
Laboratory Spotlight at ExosomeDx for Testing Samples
Pharma Spotlight to Help Treat Prostate Cancer at the Right Time
Walkthrough to the Lab with Dr. Johan Skog Spotlight with Exosome Based Prostate Cancer Test
Human Resources Spotlight - Making an Impact in Healthcare
Customer Service Spotlight - Making an Impact for Patients
ExosomeDx: This is Who We Are